Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background & Aims: Longitudinal data are scarce regarding the natural history and long-term risk of mortality, in children and young adults with biopsy-confirmed nonalcoholic fatty liver disease (NAFLD). Methods: This nationwide, matched cohort study included all Swedish children and young adults (≤25 years) with biopsy-confirmed NAFLD (1966–2017; n=718). NAFLD was confirmed histologically from all liver biopsies submitted to Sweden’s 28 pathology departments, and further categorized as simple steatosis or steatohepatitis (NASH). NAFLD patients were matched to ≤5 general population controls by age, sex, calendar year and county (n=3,457). To account for shared genetic and early-life factors, we also matched NAFLD patients to full-sibling comparators. Using Cox regression, we estimated multivariable-adjusted hazard ratios (aHRs) and 95%CIs. Results: Over a median of 15.8 years, 59 NAFLD patients died (5.5/1000 person-years [PY]), compared to 36 population controls (0.7/1000PY; difference=4.8/1000PY; multivariable aHR=5.88 [95%CI=3.77–9.17]), corresponding to 1 additional death per each 15 patients with NAFLD, followed for 20 years. The 20-year absolute risk of overall mortality was 7.7% among NAFLD patients, and 1.1% among controls (difference=6.6%, 95%CI=4.0–9.2). Findings persisted after excluding subjects who died within the first 6 months (aHR=4.65, 95%CI=2.92–7.42), and after using full-sibling comparators (aHR=11.72, 95%CI=3.18–43.23). Simple steatosis was associated with a 5.26-fold higher adjusted rate of mortality, compared to controls (95%CI=3.05–9.07), and this was amplified with NASH (aHR=11.51, 95%CI=4.77–27.79). Most of the excess mortality was from cancer (1.67 vs. 0.07/1000PY; aHR=15.60, 95%CI=4.97–48.93), liver disease (0.93 vs. 0.04/1000PY; aHR=16.46, 95%CI=2.75–98.43) and cardiometabolic disease (1.12 vs. 0.14/1000PY; aHR=4.32, 95%CI=1.73–10.79). Conclusions: Swedish children and young adults with biopsy-confirmed NAFLD have significantly higher rates of overall, cancer-, liver- and cardiometabolic-specific mortality, compared to matched general population controls.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abarca-Gómez, L., Abdeen, Z. A., Hamid, Z. A., Abu-Rmeileh, N. M., Acosta-Cazares, B., Acuin, C., Adams, R. J., Aekplakorn, W., Afsana, K., Aguilar-Salinas, C. A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32129-3 · Cited by 7,482
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
External review and validation of the Swedish national inpatient register
Ludvigsson, J. F., Andersson, E., Ekbom, A., Feychting, M., Kim, J.-L., Reuterwall, C., Heurgren, M., & Olausson, P. O. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-450 · Cited by 5,055
Self-citationIntroduction to the Analysis of Survival Data in the Presence of Competing Risks
Austin, P. C., Lee, D. S., & Fine, J. P. (2016) · Circulation · doi:10.1161/circulationaha.115.017719 · Cited by 2,653
Must, A., Jacques, P. F., Dallal, G. E., Bajema, C. J., & Dietz, W. H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211053271904 · Cited by 2,233
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Wettermark, B., Hammar, N., MichaelFored, C., Leimanis, A., Otterblad Olausson, P., Bergman, U., Persson, I., Sundström, A., Westerholm, B., & Rosén, M. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1294 · Cited by 1,887
Taylor, R. S., Taylor, R. J., Bayliss, S., Hagström, H., Nasr, P., Schattenberg, J. M., Ishigami, M., Toyoda, H., Wai-Sun Wong, V., Peleg, N., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.043 · Cited by 1,069
Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort
Simon, T. G., Roelstraete, B., Khalili, H., Hagström, H., & Ludvigsson, J. F. (2021) · Gut · doi:10.1136/gutjnl-2020-322786 · Cited by 673
Self-citation
Cited by
Advancing the global public health agenda for NAFLD: a consensus statement
Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M. A., et al. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00523-4 · Cited by 757
Pediatric obesity—Long‐term consequences and effect of weight loss
Marcus, C., Danielsson, P., & Hagman, E. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13547 · Cited by 267
Zonation in NASH – A key paradigm for understanding pathophysiology and clinical outcomes
Steinman, J. B., Salomao, M. A., & Pajvani, U. B. (2021) · Liver International · doi:10.1111/liv.15025 · Cited by 49
Hepatic Steatosis in Patients with Celiac Disease: The Role of Packaged Gluten-Free Foods
Raiteri, A., Granito, A., Faggiano, C., Giamperoli, A., Catenaro, T., Negrini, G., & Tovoli, F. (2022) · Nutrients · doi:10.3390/nu14142942 · Cited by 20
“Alarmingly, recent evidence suggested that NAFLD also increases long-term mortality for cancer, liver disease, and cardiovascular disease in children and young adults [8].”
BackgroundSharma, N., Singh, L., Sharma, A., Kumar, A., & Mahajan, D. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107375 · Cited by 16
Metadata
- Authors
- Simon, T. G., Roelstraete, B., Hartjes, K., Shah, U., Khalili, H., Arnell, H., & Ludvigsson, J. F.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 75
- Issue
- 5
- Pages
- 1034-1041
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W3176502621
- Cited by
- 149
- References
- 9
- FWCI
- 12.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.